ATMOverview.jpg
ATM-cancer_risks.png
ATM-associated_syndrome (1).png
medical_managment-key.png

CANCER

GENETIC CANCER RISK

Female Breast

High Risk

Pancreatic

High Risk

Prostate

High Risk

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

RISK FOR GENERAL POPULATION *

Female Breast

To age 50

Up to 9%

2.0%

To age 80

17%-52%

10.6%

Pancreatic

To age 80

5%

1.1%

Prostate

To age 80

26%-42%

10.1%

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Female Breast

Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.

Individualized

NA

Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling

When genetic risk is identified, but not before age 21

Every 6 to 12 months

Mammography with consideration of tomosynthesis and consideration of breast MRI with contrast

Age 40, or modified to a younger age based on the family history of breast cancer

Annually

Consider additional risk-reduction strategies.

Individualized

NA

Pancreatic

For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.

Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family

Annually

Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.

Individualized

Individualized

Prostate

Incorporating information about increased risk due to gene mutation, start risk and benefit discussion about offering baseline digital rectal examination (DRE) and Prostate Specific Antigen (PSA).15

Age 40

Individualized, consider annually

ATM-unique_challenges.png